Vebreltinib
Phase 3Small molecule
Vebreltinib is one of 111 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
5
Indications
6
Total Trials
6
Active Trials
110
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1SHR-A1811
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
HLX43
Shanghai Henlius BiotechPhase 3
Vebreltinib
AAvistone Biotechnology Co., Ltd.
Phase 3
BPI-7711
BBeta Pharma Shanghai
Phase 3
Remeron
OOrganon and Co
Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally Advanced or Metastatic NSCLC2 trials
MET Amplification1 trial
Non-Small Cell Lung Cancer1 trial
Metastatic1 trial
Vebreltinib for Advanced or Metastatic CCS
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07153887·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vebreltinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAvistone Biotechnology Co., Ltd.